Advanced

Development of macrolide resistance in Mycoplasma pneumoniae-infected Swedish patients treated with macrolides.

Nilsson, Anna LU ; Jensen, Jørgen Skov; Björkman, Per LU and Persson, Kenneth LU (2014) In Scandinavian Journal of Infectious Diseases 46(4). p.315-319
Abstract
Background: The proportion of Mycoplasma pneumoniae isolates carrying point mutations in the 23S region of the genome associated with macrolide resistance has increased. We evaluated the probability of developing M. pneumoniae macrolide resistance mutations during macrolide treatment. Methods: M. pneumoniae strains from initial and follow-up oropharyngeal samples from 38 Swedish patients were tested for 23S rRNA mutations by amplifying and pyrosequencing the gene target region. The duration of symptoms and of M. pneumoniae carriage were recorded in cases with and without the macrolide resistance mutation. Results: Macrolide resistance mutations were absent in all baseline strains. Twenty-two patients were prescribed macrolides; the longest... (More)
Background: The proportion of Mycoplasma pneumoniae isolates carrying point mutations in the 23S region of the genome associated with macrolide resistance has increased. We evaluated the probability of developing M. pneumoniae macrolide resistance mutations during macrolide treatment. Methods: M. pneumoniae strains from initial and follow-up oropharyngeal samples from 38 Swedish patients were tested for 23S rRNA mutations by amplifying and pyrosequencing the gene target region. The duration of symptoms and of M. pneumoniae carriage were recorded in cases with and without the macrolide resistance mutation. Results: Macrolide resistance mutations were absent in all baseline strains. Twenty-two patients were prescribed macrolides; the longest M. pneumoniae carriage time in these patients was 7 months and the longest symptomatic period was 7.5 months. Macrolide resistance was detected after macrolide treatment in 1 patient (carriage time 3.5 months and symptomatic period 7.5 months). Conclusions: M. pneumoniae may develop macrolide resistance during macrolide treatment. A long duration of M. pneumoniae carriage and symptoms is common in patients regardless of the presence of resistance. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Infectious Diseases
volume
46
issue
4
pages
315 - 319
publisher
Informa Healthcare
external identifiers
  • pmid:24447251
  • wos:000333045600011
  • scopus:84898939792
ISSN
1651-1980
DOI
10.3109/00365548.2013.866268
language
English
LU publication?
yes
id
5b611edb-6761-4851-9c9c-452b291b62b5 (old id 4290954)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24447251?dopt=Abstract
date added to LUP
2014-02-07 15:32:32
date last changed
2017-08-20 03:07:29
@article{5b611edb-6761-4851-9c9c-452b291b62b5,
  abstract     = {Background: The proportion of Mycoplasma pneumoniae isolates carrying point mutations in the 23S region of the genome associated with macrolide resistance has increased. We evaluated the probability of developing M. pneumoniae macrolide resistance mutations during macrolide treatment. Methods: M. pneumoniae strains from initial and follow-up oropharyngeal samples from 38 Swedish patients were tested for 23S rRNA mutations by amplifying and pyrosequencing the gene target region. The duration of symptoms and of M. pneumoniae carriage were recorded in cases with and without the macrolide resistance mutation. Results: Macrolide resistance mutations were absent in all baseline strains. Twenty-two patients were prescribed macrolides; the longest M. pneumoniae carriage time in these patients was 7 months and the longest symptomatic period was 7.5 months. Macrolide resistance was detected after macrolide treatment in 1 patient (carriage time 3.5 months and symptomatic period 7.5 months). Conclusions: M. pneumoniae may develop macrolide resistance during macrolide treatment. A long duration of M. pneumoniae carriage and symptoms is common in patients regardless of the presence of resistance.},
  author       = {Nilsson, Anna and Jensen, Jørgen Skov and Björkman, Per and Persson, Kenneth},
  issn         = {1651-1980},
  language     = {eng},
  number       = {4},
  pages        = {315--319},
  publisher    = {Informa Healthcare},
  series       = {Scandinavian Journal of Infectious Diseases},
  title        = {Development of macrolide resistance in Mycoplasma pneumoniae-infected Swedish patients treated with macrolides.},
  url          = {http://dx.doi.org/10.3109/00365548.2013.866268},
  volume       = {46},
  year         = {2014},
}